Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07593872

XR-Assisted PET/CT Navigation for Cervical Lymph Node Dissection in Lung Cancer

This single-arm, prospective feasibility study evaluates an Extended Reality (XR) headset-based preoperative surgical planning workflow that fuses 18F-FDG PET metabolic hotspots with CT anatomy on the OpVerse platform, in patients with non-small cell lung cancer (NSCLC) and supraclavicular or cervical lymph node metastasis (N3 disease) requiring lymph node dissection. Ten participants will undergo standard preoperative contrast-enhanced CT and whole-body PET. Synapse 3D software is used to segment key anatomic structures (clavicle, sternocleidomastoid, internal jugular vein, subclavian vessels, brachial plexus) and to project PET SUV hotspots onto the high-resolution CT model, yielding a patient-specific digital twin of functional tumor boundaries and at-risk neurovascular structures.

Immediately prior to skin incision, the operating surgeon dons an XR head-mounted display (HoloLens via OpVerse) and registers the digital twin to the patient's neck using stable bony landmarks (clavicular head, sternal notch, mastoid). The surgeon plans the optimal incision and initial dissection trajectory, avoiding superficial veins and projecting the location of deep PET-positive nodes. The XR device is then removed, and the planned cervical or supraclavicular lymph node dissection is performed using standard surgical technique without further intraoperative XR guidance.

The primary endpoint is a composite of safety and feasibility: absence of Grade ≥2 (Clavien-Dindo) phrenic nerve, brachial plexus, chyle leak, Horner syndrome, or major vascular injury through 30 days postoperatively, together with successful XR registration and incision planning. Secondary endpoints include incision planning accuracy, PET hotspot clearance rate, target registration error, operative time, estimated blood loss, and lymph node yield.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Background and Rationale NSCLC with supraclavicular or cervical lymph node metastasis (N3 disease) was historically considered unresectable. With the advance of multimodal therapy, complete lymph node dissection in selected patients has been shown to improve locoregional control. However, the supraclavicular fossa - frequently described as 'Pandora's Box' - is anatomically narrow and dense, with metastatic nodes often abutting the subclavian vessels, internal jugular vein, phrenic nerve, and brachial plexus. Conventional surgery relies heavily on the surgeon's tactile experience and 2D mental reconstruction of preoperative CT, increasing the risk of inadvertent neurovascular injury and incomplete clearance of post-treatment fibrotic versus active disease.

Intervention This study integrates two complementary technologies. (1) Multimodal image fusion using Fujifilm Synapse 3D maps PET SUV hotspots representing biologically active tumor onto a high-resolution CT anatomical model, producing a patient-specific digital twin. The fused model is exported to a static 3D format (OBJ/STL) and imported into the OpVerse XR platform - an offline data-conversion workflow with no real-time API coupling between the two systems, ensuring system stability and software compatibility. (2) Preoperative XR planning: in the operating room after general anesthesia and head/neck positioning, the surgeon wears an XR head-mounted display (HoloLens) and performs surface registration using stable bony landmarks. The 'see-through' overlay enables the surgeon to identify subcutaneous tumor hotspots and superficial venous anatomy, and to mark the optimal skin incision and initial dissection trajectory before any cut is made. The XR headset is then removed; lymph node dissection proceeds using standard sterile technique. Therefore the device functions purely as a preoperative visual aid (Non-Significant Risk), without entry into the sterile operative field.

Lymph node dissection definition En bloc systematic resection of the fibrofatty tissue containing metastatic nodes within the defined cervical or supraclavicular region, to achieve oncologic clearance and provide adequate tissue for pathologic staging and next-generation sequencing.

Statistical analysis All analyses are performed using SPSS. Continuous variables (operative time, blood loss, lymph node count) are summarized as mean ± SD or median; categorical variables (complications, registration success) as frequency and percentage. Successful completion rate of the XR-assisted workflow is reported with 95% confidence intervals. As a single-arm feasibility trial, no formal hypothesis testing is planned.

Preliminary data The investigators have completed a prior pilot trial (REC 202502149RINB, 2025) of XR-assisted lung nodule localization in 20 patients undergoing thoracoscopic sublobar resection, achieving 6-7 mm mean target registration error and 19/20 successful localizations without major complications. Because the supraclavicular region is more rigidly tethered to the bony skeleton and less affected by respiratory motion, registration accuracy in the present study is expected to be ≤5 mm.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 to 80 years.
  • Confirmed or highly suspected lung cancer with supraclavicular or cervical lymph node metastasis requiring lymph node dissection.
  • Willing to undergo preoperative PET/CT imaging.
  • Able to provide written informed consent.

Exclusion criteria

  • Prior high-dose radiation therapy to the neck causing severe distortion of cervical anatomy.
  • Inability to undergo imaging studies, or known allergy to iodinated contrast media.
  • Vulnerable populations as defined by local IRB regulations (e.g., pregnant women, prisoners, individuals lacking decisional capacity).

Treatment and study plan

OpVerse XR Surgical Planning Platform with HoloLens HMD

Device

An offline workflow in which patient-specific PET/CT-fused 3D models built in Synapse 3D are exported to OBJ/STL format and rendered via the OpVerse platform on a HoloLens head-mounted display. The surgeon performs surface registration to bony landmarks of the neck and shoulder for preoperative incision planning. The device is removed prior to skin incision and is not used during the sterile dissection.

Cervical / Supraclavicular Lymph Node Dissection

Procedure

En bloc systematic resection of fibrofatty tissue and metastatic lymph nodes within the cervical or supraclavicular region, performed using standard open surgical technique after XR-assisted incision planning.

Primary outcomes

  1. Successful Completion of XR-Assisted Preoperative Surgical Planning Workflow

    Time frame: Intraoperatively, prior to skin incision (Day 0)

    Proportion of participants in whom the complete XR-assisted preoperative planning workflow is successfully executed, defined as meeting ALL of the following technical criteria:

    • Successful import and rendering of the patient-specific PET/CT fused 3D digital twin (OBJ/STL format) on the OpVerse platform via the HoloLens head-mounted display.
    • Successful surface registration to the patient's bony landmarks (clavicular head, sternal notch, mastoid) with a Target Registration Error (TRE) of 5 mm or less.
    • Successful surgeon-performed marking of the optimal skin incision and initial dissection trajectory prior to skin incision. The endpoint is reported as the percentage of cases (out of 10) meeting all three criteria.

Secondary outcomes

  1. Incidence of Procedure-Related Adverse Events

    Time frame: From surgery through 30 days postoperatively

    Proportion of participants experiencing Grade ≥2 (Clavien-Dindo classification) adverse events related to the surgical procedure, including phrenic nerve injury, brachial plexus injury, chyle leak, Horner syndrome, or major vascular injury.

  2. Surgeon-Assessed Adequacy of XR-Planned Surgical Incision (3-Point Categorical Scale)

    Time frame: Intraoperatively, at time of skin incision and during initial dissection (Day 0)

    Adequacy of the XR-planned skin incision in exposing the targeted lymph nodes, assessed intraoperatively by the operating surgeon using a 3-point categorical scale:

    • Grade 1 (Adequate): the planned incision provides sufficient exposure of all targeted lymph nodes; no modification required.
    • Grade 2 (Minor modification): the planned incision requires extension of 2 cm or less to achieve adequate exposure.
    • Grade 3 (Major modification): the planned incision requires extension of more than 2 cm, or repositioning to a different skin site, to achieve adequate exposure.

    The endpoint is reported as the proportion of cases (out of 10) in each grade.

  3. PET Hotspot Clearance Rate

    Time frame: At time of surgery

    Proportion of preoperatively identified PET-positive lymph nodes (SUV hotspots) that are completely resected, confirmed by review of the operative specimen against preoperative imaging.

  4. Target Registration Error (TRE)

    Time frame: At time of surgery

    Mean spatial offset (millimeters) between virtual model bony landmarks and corresponding patient anatomy after XR surface registration.

  5. Operative Time

    Time frame: At time of surgery

    Total time from skin incision to skin closure (minutes).

  6. Estimated Intraoperative Blood Loss

    Time frame: At time of surgery

    Volume of blood loss recorded during the procedure (milliliters).

Study contacts

Contact information is provided by the study sponsor or research team.

Chih-Hsiang Chang

CONTACT

[email protected]

+886-2-2312-3456 ext. 53384

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Registry information

Official study title

Application of Extended Reality (XR)-Assisted PET/CT Fusion Navigation in Supraclavicular-to-Cervical Lymph Node Dissection for Lung Cancer

Acronym: XR-NeckLND

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
May 18, 2026
Registry last updated
May 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.